This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. Phil., President of Research at Idera Pharmaceuticals. Some Professional Tips On Prudent Tactics Of Glaucoma | Savannah Owens TravelWe are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. About Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Ideras proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com . Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements about potential treatments for cancer or other diseases employing combinations of drug therapies including Ideras third generation gene silencing technology. Such statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on the companys current beliefs and expectations.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html
Clinical Ophthalmology. The iris is the coloured part of the eye near the front. Sometimes uveitis is not so subtle with large numbers of cells visible and accumulations on the back of the cornea the clear “dome-shaped” front cover of the eye. The inflammation may be linked with autoimmune diseases, but most cases occur in healthy people. Complementary and Alternative Therapies’ Uveitis needs conventional medical treatment. Sin embargo, suede ester ligada a la enfermedad de Cohn y posiblemente a la sclerosis multiple. The disease will cause symptoms, such as decreased vision, pain, light sensitivity, and increased floaters. Eventually, the eye will naturally replace the vitreous humour with a slightly different clear fluid called aqueous humour. Inflammation of the choroid is called choroiditis. The fluid inside the eye will be temporarily replaced during the operation with either a bubble of air or petrol or a mixture of the two, or a liquid substitute. Diffuse uveitis has a combination of symptoms of all types of uveitis. AskMayoExpert. Lyon F, Gale RP, Lightman S. Acute anterior uveitis presents as follows: 2 Pain, generally developing over a few hours or days except in cases of trauma Chronic anterior uveitis presents primarily as blurred vision and mild redness.
Uveitis.s inflammation of a part of the eye called the urea. Medline . The goal of treatment is to reduce the inflammation in the eye. http://www.aprasw.org/advisingeyesurgeon/2016/08/29/some-helpful-tips-on-trouble-free-systems-of-keratoconus/Inflammation is the body’s natural response to tissue damage, germs, or toxins. The injection can be given to the side of the eye subconjunctival or around the eye periocular. Severe cases of uveitis may require drugs that suppress the immune system. Press release issued by allergen in June 2014. Rare cases are chronic and require close, long term monitoring.